170 related articles for article (PubMed ID: 33085768)
1. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Gilbert MR; Yuan Y; Wu J; Mendoza T; Vera E; Omuro A; Lieberman F; Robins HI; Gerstner ER; Wu J; Wen PY; Mikkelsen T; Aldape K; Armstrong TS
Neuro Oncol; 2021 Mar; 23(3):468-477. PubMed ID: 33085768
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Rudà R; Bosa C; Magistrello M; Franchino F; Pellerino A; Fiano V; Trevisan M; Cassoni P; Soffietti R
Neuro Oncol; 2016 Feb; 18(2):261-8. PubMed ID: 26323606
[TBL] [Abstract][Full Text] [Related]
3. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
DeWire M; Fouladi M; Turner DC; Wetmore C; Hawkins C; Jacobs C; Yuan Y; Liu D; Goldman S; Fisher P; Rytting M; Bouffet E; Khakoo Y; Hwang EI; Foreman N; Stewart CF; Gilbert MR; Gilbertson R; Gajjar A
J Neurooncol; 2015 May; 123(1):85-91. PubMed ID: 25859842
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
Chamberlain MC; Johnston SK
Cancer; 2009 Oct; 115(20):4775-82. PubMed ID: 19569246
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for intracranial ependymoma in adults.
Gramatzki D; Roth P; Felsberg J; Hofer S; Rushing EJ; Hentschel B; Westphal M; Krex D; Simon M; Schnell O; Wick W; Reifenberger G; Weller M
BMC Cancer; 2016 Apr; 16():287. PubMed ID: 27108407
[TBL] [Abstract][Full Text] [Related]
7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Komori K; Yanagisawa R; Miyairi Y; Sakashita K; Shiohara M; Fujihara I; Morita D; Nakamura T; Ogiso Y; Sano K; Shirahata M; Fukuoka K; Ichimura K; Shigeta H
Pediatr Blood Cancer; 2016 Jan; 63(1):152-5. PubMed ID: 26305586
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Grauer O; Pascher C; Hartmann C; Zeman F; Weller M; Proescholdt M; Brawanski A; Pietsch T; Wick W; Bogdahn U; Hau P
J Neurooncol; 2011 Sep; 104(3):801-9. PubMed ID: 21373969
[TBL] [Abstract][Full Text] [Related]
10. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma.
Lombardi G; Pambuku A; Bellu L; Della Puppa A; Rumanò L; Gardiman MP; Pomerri F; Zagonel V
Chemotherapy; 2013; 59(3):176-80. PubMed ID: 24192541
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Han SJ; Rolston JD; Molinaro AM; Clarke JL; Prados MD; Chang SM; Berger MS; DeSilva A; Butowski NA
Neuro Oncol; 2014 Sep; 16(9):1255-62. PubMed ID: 24670608
[TBL] [Abstract][Full Text] [Related]
13. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D
J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY
J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Karavasilis V; Kotoula V; Pentheroudakis G; Televantou D; Lambaki S; Chrisafi S; Bobos M; Fountzilas G
J Neurol; 2013 Jun; 260(6):1469-80. PubMed ID: 23292205
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Gan HK; Rosenthal MA; Dowling A; Kalnins R; Algar E; Wong N; Benson A; Woods AM; Cher L
Neuro Oncol; 2010 May; 12(5):500-7. PubMed ID: 20406900
[TBL] [Abstract][Full Text] [Related]
17. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
Sardi I; Cetica V; Massimino M; Buccoliero AM; Giunti L; Genitori L; Aricò M
Oncol Rep; 2009 Oct; 22(4):773-9. PubMed ID: 19724855
[TBL] [Abstract][Full Text] [Related]
19. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
[TBL] [Abstract][Full Text] [Related]
20. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Armstrong TS; Wefel JS; Wang M; Gilbert MR; Won M; Bottomley A; Mendoza TR; Coens C; Werner-Wasik M; Brachman DG; Choucair AK; Mehta M
J Clin Oncol; 2013 Nov; 31(32):4076-84. PubMed ID: 24101048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
